首页工具

登录

搜索结果

Search Results for " pik3ca "

如果没找到您满意的产品或者您对产品有其他要求，可以联系我们专业顾问为您提供针对性的合理建议。 QQ咨询网站留言咨询

Cat. No.	Product Name	Target	Signaling Pathways
T1921	Alpelisib BYL-719	PI3K	PI3K/Akt/mTOR signaling
	Alpelisib (BYL-719) 是一种 PI3Kα 抑制剂 (IC50=5 nM)，具有选择性、有效性和口服活性。Alpelisib 以较低活性抑制 PI3Kβ/γ/δ (IC50=250/290/1200 nM)。Alpelisib 具有抗肿瘤活性，对 PIK3CA 突变肿瘤具有靶向性。
T1952	MK-2206 dihydrochloride MK-2206 2HCl	Apoptosis; Akt; Autophagy	Apoptosis; Autophagy; Cytoskeletal Signaling; PI3K/Akt/mTOR signaling
	MK-2206 dihydrochloride (MK-2206 2HCl) 是一种变构 Akt 抑制剂，抑制 Akt1、Akt2 和 Akt3 (IC50=8/12/65 nM)，具有口服活性的、高效选择性。MK-2206 dihydrochloride 具有抗肿瘤活性。
T14511	BAY1082439 N-[8-[[(2R)-2-羟基-3-(吗啉-4-基)丙基]氧基]-7-甲氧基-2,3-二氢咪唑并[1,2-C]喹唑啉-5-基]-2-甲基吡啶-3-甲酰胺	Apoptosis; PI3K	Apoptosis; PI3K/Akt/mTOR signaling
	BAY1082439 是一种具有口服活性的，选择性 PI3Kα/β/δ抑制剂。它也能抑制 PIK3CA 的突变形式，它对抑制 Pten 丢失的前列腺癌的生长有很强的作用。
T67703	mTOR inhibitor 9b	mTOR	PI3K/Akt/mTOR signaling
	mTOR inhibitor 9b 是一种酶抑制剂，对蛋白激酶mTOR 和磷脂酰肌醇 3-激酶 PIK3CA 具有抑制作用，IC50分别为 0.76nm 和1.262 µM。mTOR inhibitor 9b 具有抗癌活性，可用来研究白血病、皮肤癌、乳腺癌、肺癌和结肠癌。
T1999	Taselisib RG-7604,GDC-0032	PI3K; Carbonic Anhydrase	Metabolism; PI3K/Akt/mTOR signaling
	Taselisib (GDC-0032) 是 PI3K 抑制剂，靶向作用于突变 PI3KCA。它能够抑制 PI3Kα (IC50:0.29 nM)，PI3Kβ (IC50:0.91 nM) 和 PI3Kγ (IC50:0.97 nM)。
T35343	MTI-31 MTI-31,LXI-15029	mTOR	PI3K/Akt/mTOR signaling
	MTI-31 (LXI-15029) 是口服有效的，高度选择性的mTORC1和mTORC2抑制剂，对 mTOR 的Kd 为 0.20 nM，IC50为 39 nM。MTI-31可用于乳腺癌的研究。
T67705	mTOR inhibitor 9a
	mTOR inhibitor 9a 对人LNCap 细胞的生长具有抑制作用，ic50为80nm。mTOR inhibitor 9a 可能具有抗肿瘤活性。
T71197	JW-7-25-1
	JW-7-25-1 is a potent multi-target inhibitor, acting on MELK, PIK3CA, mTOR, GSK3A and CDK7.
T27621	Ipatasertib HCl GDC0068,RG 7440,GDC 0068,RG-7440,GDC-0068,RG7440
	Ipatasertib is an orally active, potent and selective Akt inhibitor with antitumor activity. Inhibition of Akt activity by Ipatasertib resulted in blockade of cell-cycle progression and reduced viability of cancer cell lines. Markers of Akt activation, in
T81784	MK-2206 free base	Akt	Cytoskeletal Signaling; PI3K/Akt/mTOR signaling
	MK-2206 free base是一种口服活性、高选择性的变构Akt抑制剂，IC50分别针对Akt1、Akt2、Akt3为8、12和65 nM 。多种乳腺癌细胞系、PIK3CA突变以及PTEN缺失细胞系对此化合物敏感，显示出抗癌活性。
T62609	MK-2206
	MK-2206 是一种具有口服具有活力的、高效选择性的变构 Akt 抑制剂，能够作用于 Akt1 (IC50: 8 nM)、Akt2 (IC50: 12 nM) 和 Akt3 (IC50: 65 nM)。许多乳腺癌细胞系、PIK3CA 突变体和 PTEN 丢失细胞系对 MK-2206 敏感。MK-2206 具有抗癌作用。
T67702	mTOR inhibitor 9d	PI3K; mTOR	PI3K/Akt/mTOR signaling
	mTOR inhibitor 9d 是一种蛋白激酶 mTOR 和PI3K 双重抑制剂，对mTOR 的IC50值为0.31nm，可用于治疗白血病、皮肤癌、乳腺癌、肺癌和结肠癌。
T38847	Vevorisertib Vevorisertib,ARQ 751
	Vevorisertib (ARQ 751) is a highly effective oral compound that selectively inhibits pan-AKT serine/threonine kinases such as AKT1 (with an IC50 value of 0.55 nM), AKT2 (with an IC50 value of 0.81 nM), and AKT3 (with an IC50 value of 1.31 nM). This compound, either as a standalone treatment option or in combination with other anti-cancer agents, is ideally suited for conducting research on solid tumors characterized by PIK3CA/AKT/PTEN mutations[4].
T70552	Ipatasertib tosylate
	Ipatasertib, also known as GDC0068, is an orally active, potent and selective Akt inhibitor. GDC-0068 blocked Akt signaling both in cultured human cancer cell lines and in tumor xenograft models. Inhibition of Akt activity by GDC-0068 resulted in blockade of cell-cycle progression and reduced viability of cancer cell lines. Markers of Akt activation, including high-basal phospho-Akt levels, PTEN loss, and PIK3CA kinase domain mutations, correlate with sensitivity to GDC-0068. In multiple tumor...
TP2288	Rapalink-1	Others	Others
	RapaLink-1 is the third-generation mTOR inhibitor exploiting the unique juxtaposition of two drugs (first- and second-generation mTOR kinase inhibitors) -binding pockets to create a bivalent interaction that allows inhibition of the mutants which has resi
T72071	WAY-299017	Antibacterial	Microbiology/Virology
	WAY-299017是一种强效且具有选择性的UPPS 抑制剂，可用于治疗细菌感染。

化合物

Cat.No: T1921

Synonym: BYL-719

Target: PI3K

MK-2206 dihydrochloride

Cat.No: T1952

Synonym: MK-2206 2HCl

Target: Apoptosis, Akt, Autophagy

Cat.No: T14511

Synonym: N-[8-[[(2R)-2-羟基-3-(吗啉-4-基)丙基]氧基]-7-甲氧基-2,3-二氢咪唑并[1,2-C]喹唑啉-5-基]-2-甲基吡啶-3-甲酰胺

Target: Apoptosis, PI3K

mTOR inhibitor 9b

Cat.No: T67703

Target: mTOR

Cat.No: T1999

Synonym: RG-7604,GDC-0032

Target: PI3K, Carbonic Anhydrase

Cat.No: T35343

Synonym: MTI-31,LXI-15029

Target: mTOR

mTOR inhibitor 9a

Cat.No: T67705

Cat.No: T71197

Ipatasertib HCl

Cat.No: T27621

Synonym: GDC0068,RG 7440,GDC 0068,RG-7440,GDC-0068,RG7440

MK-2206 free base

Cat.No: T81784

Target: Akt

Cat.No: T62609

mTOR inhibitor 9d

Cat.No: T67702

Target: PI3K, mTOR

Cat.No: T38847

Synonym: Vevorisertib,ARQ 751

Ipatasertib tosylate

Cat.No: T70552

Cat.No: TP2288

Target: Others

Cat.No: T72071

Target: Antibacterial

我们的所有产品和服务仅用于科学研究，不能被用于人体，我们也不向个人提供产品和服务。

Copyright © 2015-2024 TargetMol Chemicals Inc. All rights reserved. 沪ICP备20019793号-4

沪公网安备 31010602006700号

沪公网安备 31010602006700号

TargetMol Loading

联系我们

电话：

400-820-0310

邮箱：

service@tsbiochem.com

QQ：

2881945090（终端用户）

2885109491（经销商）

经销：

终端：

地址：

上海市静安区江场三路238号8楼